1. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up
- Author
-
Bridges, K., Telfer, M., Ataga, Kenneth, Orringer, E., Hoehner, C., Hernandez, S., Valdez, S., Temple, D., Shurin, S., Johnson-Telfair, A., Hagar, W., Vichinsky, E., Smith, Wally, Steinberg, Martin H., Kleman, K., Rosse, W., Waller, L., Barber, Y., Chow, J., Gascon, P., Winograd, C., Di Paolo, P., Hui, M., Moshang, J., Olivieri, N., Dorn, L., Siteman, J., Embury, S., Eckman, J., Ballas, Samir K., Anderson, A., White, L., Harrington, T., Talischy-Zahed, N., Shaw, D., Scott, B., Waclawiw, Myron A., Labrousse, W., Adler, B., Phillips, G., Bigelow, C., Armstrong, F. Danny, Chiarucci, K., Childerie, S., McLaughlin, K., Mandell, E., DeCastro, Laura, Claster, S., Knors, V., Gargiulo, S., Jones, S., Tynan, B., Saunthararajah, Y., Saunders, T., Maddox, B., Hackney-Stevens, E., Keverline, L., Gardner, D., Carter-Randall, E., Schmidt, B., Tracy, A., Davies, D., Carlos, T., Kutlar, Abdullah, Finke, H., Nwokolo, C., Perlin, E., Onyekwere, O. C., Okam, M., Peace, D., Milner, P., Koshy, M., Sheikhai, M., Daitch, L., Swerdlow, Paul, Pendarvis, G., Harrell, R., Case, E., Brenner, A., Bailey, J. H., Strayhorn, D., Prchal, J., Ramirez, G., Dosik, H., Platt, A., McGee, M., Lewis, N., Castro, Oswaldo, Palmer, A., Wilkes, E., Braddock, J., Sabahi, V., Pegelow, C., Bellevue, R., McArdle, T., O'Brien, R., Williams, K., Usry, L., Eskridge, L., Berman, B., Allen, G. E., Earles, A., Bryan, M., Davis, A., Rodriguez, E. M., Souffrant, H., Genther, K., McCarthy, William F., Roundtree-Schmotzer, A., and Ryans, P.
- Abstract
A randomized, controlled clinical trial established the efficacy and safety of short-term use of hydroxyurea in adult sickle cell anemia. To examine the risks and benefits of long-term hydroxyurea usage, patients in this trial were followed for 17.5 years during which they could start or stop hydroxyurea. The purpose of this follow-up was to search for adverse outcomes and estimate mortality. For each outcome and for mortality, exact 95% confidence intervals were calculated, or tests were conducted at α = 0.05 level (p-value
- Published
- 2010
- Full Text
- View/download PDF